Calcium channel blockers for people with chronic kidney disease requiring dialysis

  • Protocol
  • Intervention

Authors

  • George A Mugendi,

    Corresponding author
    1. University of Nairobi, Pharmaceutics and Pharmacy Practice, School of Pharmacy, Nairobi, Nairobi, Kenya
    • George A Mugendi, Pharmaceutics and Pharmacy Practice, School of Pharmacy, University of Nairobi, PO Box 19676, Nairobi, Nairobi, 00202, Kenya. gendike@gmail.com.

    Search for more papers by this author
  • Giovanni FM Strippoli,

    1. The Children's Hospital at Westmead, Cochrane Renal Group, Centre for Kidney Research, Westmead, NSW, Australia
    2. University of Bari, Department of Emergency and Organ Transplantation, Bari, Italy
    3. Mario Negri Sud Consortium, Department of Clinical Pharmacology and Epidemiology, Santa Maria Imbaro, Italy
    4. The University of Sydney, Sydney School of Public Health, Sydney, Australia
    5. Diaverum, Medical-Scientific Office, Lund, Sweden
    Search for more papers by this author
  • Florence M Mutua,

    1. University of Nairobi, Department of Medical Microbiology, College of Health Sciences, Nairobi, Kenya
    Search for more papers by this author
  • Tonya M Esterhuizen

    1. Stellenbosch University, Centre for Evidence-based Health Care, Faculty of Medicine and Health Sciences, Cape Town, South Africa
    Search for more papers by this author

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

This review aims to look at the benefits and harms of CCB for people with CKD requiring dialysis.